

Variant: *NM_000314.8(PTEN):c.16A>G (p.Lys6Glu)*

Version: 1.0

CA377781810 [↗](#)

644390 (ClinVar) [↗](#)

Gene: PTEN ([HGNC:5728](#))

Condition: PTEN hamartoma tumor syndrome ([MONDO:0017623](#))

Inheritance Mode: Autosomal dominant inheritance

UUID: 42dd26e4-54dd-4c3b-abdc-5f9f3dac0795

Approved on: 2021/6/4

Published on: 2022/9/30

HGVS expressions

NM_000314.8:c.16A>G

NM_000314.8(PTEN):c.16A>G (p.Lys6Glu)

NC_000010.11:g.87864485A>G

CM000672.2:g.87864485A>G

NC_000010.10:g.89624242A>G

CM000672.1:g.89624242A>G

NC_000010.9:g.89614222A>G

NG_007466.2:g.6047A>G

NG_033079.1:g.3953T>C

ENST00000700029.2:c.16A>G

ENST00000710265.1:c.16A>G

ENST00000472832.3:c.16A>G

ENST00000688922.2:c.16A>G

ENST00000700021.1:c.16A>G

ENST00000700022.1:c.16A>G

ENST00000706954.1:c.16A>G

ENST00000706955.1:c.16A>G

ENST00000686459.1:c.16A>G

ENST00000688158.1:c.16A>G

ENST00000688308.1:c.16A>G

ENST00000693560.1:c.535A>G

ENST00000371953.8:c.16A>G

ENST00000371953.7:c.16A>G

ENST00000462694.1:n.18A>G

ENST00000487939.1:n.37A>G

ENST00000610634.1:c.-87A>G

NM_000314.5:c.16A>G

NM_000314.6:c.16A>G

NM_001304717.2:c.535A>G

NM_001304718.1:c.-690A>G

NM_000314.7:c.16A>G

NM_001304717.5:c.535A>G

NM_001304718.2:c.-690A>G

Pathogenic

PS3_Supporting PP2 PM2
PS2_Very Strong PS4_Moderate

PTEN VCEP

Criteria Specification Information

- Criteria Specification: ClinGen PTEN Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 2
- Criteria Specification Approval History
- Criteria Specifications for this VCEP

Evidence submitted by expert panel

PTEN VCEP

PTEN c.16A>G (p.Lys6Glu) meets criteria to be classified as pathogenic for PTEN Hamartoma Tumor syndrome in an autosomal dominant manner using modified ACMG criteria (PMID 30311380). Please see a summary of the rules and criteria codes in the “PTEN ACMG Specifications Summary” document (assertion method column). PS2_VS: One proven plus two assumed de novo observations in a patient with the disease and no family history. (internal laboratory contributor(s) SCV001369131.2, SCV001819316.1) PS4_M: Probands with phenotype specificity score of 2-3.5. (internal laboratory contributor(s) SCV001819316.1) PM2: Absent in large sequenced populations (PMID 27535533). PP2: PTEN is defined by the PTEN Expert Panel as a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease. PS3_P: Abnormal in vitro cellular assay or transgenic model with phenotype different from wild type that does not meet PS3. (PMID 32366478, PMID 32350270, PMID 29706350)

Met criteria codes

PS3_Supporting			VCEP approved criteria based on combined published evidence suggesting some functional impact, but not strong enough for full PS3
			score -1.62 (hypomorphic range) PubMed:29706350 WT-like abundance, indicating protein stability PubMed:29785012 no impact on stability, but LOF with respect to lipid phosphatase and some additional studies PubMed:32350270 partial LOF on spheroid formation and yeast assays, slight instability PubMed:32366478
PP2			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM2			absent
PS2_Very Strong			Internal lab cases SCV001369131.2, SCV001819316.1
PS4_Moderate			Internal lab cases, 3 total phenotype specificity points (SCV001819316.1)

Curation History

▾

▾

Showing 1 to 1 of 1 rows

--

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.